The therapeutic efficacy of fractionated radiotherapy and gamma-knife radiosurgery for craniopharyngiomas. 2011

Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
Pusan National University School of Medicine, Busan, South Korea.

There is no consensus regarding the optimal timing of radiation treatment (RT) for residual or recurrent craniopharyngioma or the preferred treatment modality between fractionated radiotherapy (FRT) and gamma-knife radiosurgery (GKRS) in terms of morbidity and efficacy. This study aims to clarify the optimal timing of RT for residual or recurrent tumors by analyzing the outcomes of RT as a salvage or adjunctive treatment, and to compare the therapeutic efficacy of FRT and GKRS. Between April 1995 and November 2009, 50 of 129 patients received RT for recurrent or residual tumors. The patients were analyzed for medical data, endocrine outcome, long-term morbidity and mortality rates, recurrence rates, and responses to adjuvant RT and GKRS. Mean progression-free survival was 92.5 months (95% confidence interval, 70.9-114.1 months). Univariate analysis revealed that pre-irradiation tumor volume was closely related to better prognosis (p=0.01). We found that there was no significant difference in recurrence between patients treated with adjuvant compared to salvage RT (p>0.05). Although we found no difference in the efficacy of FRT and GKRS, five patients were newly diagnosed with hypopituitarism following RT. We concluded that RT has a very high rate of tumor control after both adjuvant or salvage RT. This study highlights the relative safety and efficacy of FRT and GKRS.

UI MeSH Term Description Entries
D007018 Hypopituitarism Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions. Adenohypophyseal Hyposecretion,Anterior Pituitary Hyposecretion Syndrome,Sheehan Syndrome,Simmonds Disease,Hyposecretion Syndrome, Anterior Pituitary,Hyposecretion, Adenohypophyseal,Pituitary Insufficiency,Postpartum Hypopituitarism,Postpartum Panhypopituitarism,Postpartum Pituitary Insufficiency,Sheehan's Syndrome,Simmonds' Disease,Disease, Simmonds,Hypopituitarism, Postpartum,Insufficiency, Pituitary,Panhypopituitarism, Postpartum,Pituitary Insufficiency, Postpartum,Sheehans Syndrome,Simmond's Disease,Syndrome, Sheehan,Syndrome, Sheehan's
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003397 Craniopharyngioma A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50) Craniopharyngioma, Adamantinous,Craniopharyngioma, Papillary,Rathke Pouch Tumor,Craniopharyngioma, Adult,Craniopharyngioma, Child,Neoplasm, Rathke Cleft,Neoplasm, Rathke's Cleft,Rathke Cleft Neoplasm,Rathke's Cleft Neoplasm,Rathke's Pouch Tumor,Adamantinous Craniopharyngioma,Adamantinous Craniopharyngiomas,Adult Craniopharyngioma,Adult Craniopharyngiomas,Child Craniopharyngioma,Child Craniopharyngiomas,Craniopharyngiomas,Craniopharyngiomas, Adamantinous,Craniopharyngiomas, Adult,Craniopharyngiomas, Child,Craniopharyngiomas, Papillary,Neoplasm, Rathkes Cleft,Papillary Craniopharyngioma,Papillary Craniopharyngiomas,Rathkes Cleft Neoplasm,Rathkes Pouch Tumor,Tumor, Rathke Pouch,Tumor, Rathke's Pouch
D005260 Female Females

Related Publications

Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
December 2000, Journal of neurosurgery,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
October 2018, Journal of neuro-oncology,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
February 2017, Neurosurgery,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
October 1998, Stereotactic and functional neurosurgery,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
November 2019, World neurosurgery,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
January 2017, Neurology India,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
January 2017, Neurology India,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
January 1999, Stereotactic and functional neurosurgery,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
November 2005, Neurosurgery,
Chiman Jeon, and Sejin Kim, and Hyung Jin Shin, and Do-Hyun Nam, and Jung-Il Lee, and Kwan Park, and Jong Hyun Kim, and ByungChan Jeon, and Doo-Sik Kong
December 2006, Journal of neurosurgery,
Copied contents to your clipboard!